I heard a story recently. This story is true, and it’s the primer for the pump this week.
It’s a story about a close associate who participates in Medicare Part D. That’s the one George W. signed into law in 2003 for prescription drug coverage.
He paid a coinsurance amount for a particular prescription of just $6 per refill in 2023. Considering his participation in the medical Part B coverage as well as Part D (both for which the patient pays a premium out of pocket monthly) this seemed right and fair.
Then…right out of the bull-riding chute, the first week of a fresh new year, voila!
All of a sudden, the same refill shoots up over $100.
Holy guacamole, how do these things happen?
I have a sneaking suspicion. Let’s explore it a bit…
The Inflation Reduction Act
It took me less than 30 seconds in the old research machine to discover that there are reforms in the near future to get out-of-pocket expenses manageable for the seniors of our great land.
To understand the effects of the Inflation Reduction Act on Medicare Part D consumers and the physicians who prescribe for them, it helps to go over the basics of Medicare Part D and the changes introduced by this Act.
Medicare Part D enrollees typically pay a monthly premium, and costs are also shared through deductibles, co-payments, and coinsurance.
The structure of Part D includes a coverage gap, often referred to as the “donut hole,” where beneficiaries may face higher out-of-pocket costs.
Inflation Reduction Act and Its Impact
The Inflation Reduction Act of 2022 introduced significant changes to Medicare, specifically targeting prescription drug prices. Key aspects include:
Negotiation of Drug Prices: For the first time, Medicare is allowed to negotiate prices for certain high-cost drugs, which could lead to lower prices for consumers.
Penalties for Price Increases: Drug companies will face penalties if they raise prices faster than inflation, which could help control cost increases.
Cap on Out-of-Pocket Costs: There’s a new $2,000 cap on out-of-pocket costs for Medicare Part D enrollees, which will significantly benefit those with high prescription drug expenses.
That sounds really awesome, doesn’t it? Don’t get too excited just yet, because for some reason Congress, in all its infinite other-influenced wisdom, has baked in a delay for this benefit until 2025.
There is a catastrophic phase clause in the new law that will effectively cap spending at $7,050 in 2024, but you have to ask yourself, “why wait the year for the $2,000 cap at all?”
I’m not what I would call a conspiracy theorist generally, but I smell a rat in the soup.
This could not have been very popular with the people that profit from pharmaceutical sales in the United States, particularly those who spend top dollar on their pet Congressperson to ensure the field remains tilted in their favor.
This, ladies and gentlemen, leads me to believe that Big Pharma has digested something that has made them a little gassy, and they’re fighting back any way they can.
Which has yours truly wondering about the cause behind my friend’s 16X-plus increase in costs.
Short-Term Effects
In the short term, consumers might experience fluctuations in drug prices, as seen in the story I just shared earlier. This could plausibly be rationalized as the market adjusting to new regulations and as drug companies recalibrate their pricing strategies in response to the Act.
The sudden increase in prescription costs at the beginning of the year could be a result of these market adjustments or specific changes in the plan’s formulary.
Long-Term Effects
In the long run, the Inflation Reduction Act is expected to reduce prescription drug costs for Medicare beneficiaries. The negotiation of drug prices and the cap on out-of-pocket costs should lead to more affordable medications for many enrollees.
However, it’s important to note that the benefits of these measures will roll out gradually over several years. There really is no such thing as a free lunch.
Impact on Physicians
For physicians, the primary impact will be indirect. Lower drug prices may improve medication adherence among patients, as cost is a significant barrier to compliance.
This could lead to better health outcomes. However, physicians might need to stay updated with changes in drug pricing and availability due to the new negotiations and regulations.
In Conclusion
The Inflation Reduction Act is intended to make significant changes in the Medicare Part D landscape, primarily beneficial to consumers in terms of reduced drug costs.
However, as with any major policy change, there will be the inevitable transitional periods of adjustment.
For physicians, the impact is more about the potential for improved patient compliance with prescribed medications due to lowered costs.
In conclusion, while challenges like rising costs and regulatory changes persist, opportunities in technology adoption, service diversification, and strategic partnerships will play a significant role in the continued growth and success of small to mid-sized medical practices in 2024.
Physician practices owners: if you would like to discuss how having a non-equity financial partner guiding your practice’s business future can increase your wealth, reduce your taxes, and provide the peace of mind that will allow you to put 110% of yourself into your patient care goals, we would like to talk to you as well.
We are still able to take two new clients at the business advisory level of service in the month of January.
Imagine the financial puzzle pieces being snapped into place for you, on your terms, so you can focus your professional clinical time on patient care.
Does that look and sound good?
Then reach out to me, and let’s talk: Free Profit & Cash Flow Analysis